Company Overview
Company Type: Private Company
Website: www.mimetogen.com
Number of Employees: -
Year Founded: 2004
Total Amount Raised (CAD mm)†: 3.32
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Mimetogen Pharmaceuticals Inc., a clinical stage biotechnology company, develops the use of peptidomimetics to treat ophthalmic diseases with high unmet medical needs. It offers MIM-D3, a compound for the treatment of dry eye syndrome; and therapeutic approaches for other ophthalmology indications, including glaucoma and other degenerative diseases of the retina, such as retinitis pigmentosa. The company was founded in 2004 and is based in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Cumberlidge, Garth 
Chief Executive Officer, President and Director
Mongrain, Francois 
Chief Financial Officer and Vice President of Finance
Brazzell, Kim 
Chief Medical Officer

Key Board Members
Name
Title
Wax, Martin B.
Chairman of the Board
Cumberlidge, Garth 
Chief Executive Officer, President and Director
Bisson, Cedric 
Director
Biswas, Sena K.
Director
Giese, Kevin A.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
1000 de La Gauchetière Street West Suite 900 | Montreal, QC | H3B 5H4 | Canada
Phone: 514 667 5869   Fax: 240 306 0500

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
VIMAC Ventures LLC
Mar-14-2006
Unknown
-
Series A
-
Schooner Capital LLC
-
Unknown
-
-
Ted Henderson

Prior Investors
Inovia Capital, Inc. (Chris Arsenault), Medwell Capital Corp., MSBi Valorisation Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-18-2013
Jul-18-2013
Private Placement
Target
Mimetogen Pharmaceuticals Inc.
Medwell Capital Corp.

0.38
Feb-25-2011
Oct-18-2011
Private Placement
Target
Mimetogen Pharmaceuticals Inc.
Inovia Capital, Inc.,VIMAC Ventures LLC,Medwell Capital Corp. Buyer Funds:VIMAC Milestone Medica Fund, L.P.

1.96
Oct-7-2009
Oct-7-2009
Private Placement
Target
Mimetogen Pharmaceuticals Inc.
Inovia Capital, Inc.,VIMAC Ventures LLC Buyer Funds:VIMAC Milestone Medica Fund, L.P.

-
Mar-14-2006
Mar-14-2006
Private Placement
Target
Mimetogen Pharmaceuticals Inc.
Inovia Capital, Inc.,VIMAC Ventures LLC Buyer Funds:VIMAC Milestone Medica Fund, L.P.

-
Oct-31-2005
Oct-31-2005
Private Placement
Target
Mimetogen Pharmaceuticals Inc.
Inovia Capital, Inc.

0.85
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Mar-31-2020
Product-Related Announcements
Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease
Nov-04-2015
Client Announcements
Allergan plc Enters into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
Sep-09-2014
Product-Related Announcements
Mimetogen Pharmaceuticals Inc. Announces Topline Results of its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome
Oct-10-2013
Product-Related Announcements
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome
Jul-18-2013
Private Placements
Mimetogen Pharmaceuticals Inc. announced that it has received CAD 0.40 million in funding from Medwell Capital Corp.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:14 PM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
33
GlobalData

Jun 23, 2023 03:01 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
18
GlobalData

Mar 23, 2023 04:02 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
18
GlobalData

Dec 19, 2022 12:44 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
18
GlobalData

Sep 28, 2022 11:45 PM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
18
GlobalData

Jun 15, 2022 01:23 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
33
GlobalData

Mar 13, 2022 02:18 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
33
GlobalData

Dec 14, 2021 02:33 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
39
GlobalData

Sep 15, 2021 04:48 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
29
GlobalData

Jun 16, 2021 10:49 AM
Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc
Reports
29


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
MIM-D3 (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Wax, Martin B.
Chairman of the Board
514 667 5869
240 306 0500
mbw817@yahoo.com
Cumberlidge, Garth 
Chief Executive Officer, President and Director
514 667 5869
240 306 0500

Bisson, Cedric 
Director
(514) 509-2083
240 306 0500
cbisson@teralyscapital.com
Biswas, Sena K.
Director
514 667 5869
240 306 0500
sbiswas@vimac.com
Giese, Kevin A.
Director
514 667 5869
240 306 0500

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cumberlidge, Garth 
Chief Executive Officer, President and Director
514 667 5869
240 306 0500

Mongrain, Francois 
Chief Financial Officer and Vice President of Finance
514 667 5869
240 306 0500

Brazzell, Kim 
Chief Medical Officer
514 667 5869
240 306 0500

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
